Although malignant astrocytomas are a leading cause of cancer-related death in children, rational therapeutic strategies are lacking. We previously identified activating mutations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) (BRAF T1799A encoding BRAF V600E ) in association with homozygous cyclin-dependent kinase inhibitor 2A (CDKN2A, encoding p14ARF and p16Ink4a) deletions in pediatric infiltrative astrocytomas. Here we report that BRAF V600E expression in neural progenitors (NPs) is insufficient for tumorigenesis and increases NP cellular differentiation as well as apoptosis. In contrast, astrocytomas are readily generated from NPs with additional Ink4a-Arf deletion. The BRAF V600E inhibitor PLX4720 significantly increased survival of mice after intracranial transplant of genetically relevant murine or human astrocytoma cells. Moreover, combination therapy using PLX4720 plus the Cyclin-dependent kinase (CDK) 4/6-specific inhibitor PD0332991 further extended survival relative to either monotherapy. Our findings indicate a rational therapeutic strategy for treating a subset of pediatric astrocytomas with BRAF V600E mutation and CDKN2A deficiency. glioma | protein kinase | tumor suppressor
Although malignant astrocytomas are a leading cause of cancer-related death in children, rational therapeutic strategies are lacking. We previously identified activating mutations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) (BRAF T1799A encoding BRAF V600E ) in association with homozygous cyclin-dependent kinase inhibitor 2A (CDKN2A, encoding p14ARF and p16Ink4a) deletions in pediatric infiltrative astrocytomas. Here we report that BRAF V600E expression in neural progenitors (NPs) is insufficient for tumorigenesis and increases NP cellular differentiation as well as apoptosis. In contrast, astrocytomas are readily generated from NPs with additional Ink4a-Arf deletion. The BRAF V600E inhibitor PLX4720 significantly increased survival of mice after intracranial transplant of genetically relevant murine or human astrocytoma cells. Moreover, combination therapy using PLX4720 plus the Cyclin-dependent kinase (CDK) 4/6-specific inhibitor PD0332991 further extended survival relative to either monotherapy. Our findings indicate a rational therapeutic strategy for treating a subset of pediatric astrocytomas with BRAF V600E mutation and CDKN2A deficiency. glioma | protein kinase | tumor suppressor T he incidence of pediatric central nervous system (CNS) tumors is second only to leukemia among malignancies affecting children (1) . Among these tumors, malignant astrocytoma, including anaplastic astrocytoma World Health Organization (WHO) grade III and glioblastoma WHO grade IV, is a leading cause of mortality. However, development of rational targeted therapies for pediatric malignant astrocytoma has been limited by inadequate information regarding the relevant underlying genetic alterations and their signaling pathway consequences. In adults, glioblastomas (GBMs) have been categorized into subtypes on the basis of gene expression patterns (2, 3) and mutations affecting core RAS, PI3-kinase, TP53, and pRB signaling pathways (4) . The spectrum and frequency of mutations in pediatric malignant astrocytoma, however, differ from that in adults. For example, whereas mutations and amplifications of EGFR are common in adult glioblastomas (GBM), they are observed only rarely in corresponding pediatric anaplastic astrocytomas or GBM (5) (6) (7) (8) (9) (10) . Similarly, mutations of PTEN and IDH1 are relatively uncommon in pediatric astrocytomas (5) . Recent studies have reported recurrent mutations of histone H3 and chromatin remodeling genes in pediatric GBM (6, 7) .
Previously, we used a whole genome approach to identify copy number variance and mutations in pediatric astrocytomas (11) . This analysis revealed activating mutations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) (BRAF T1799A encoding BRAF V600E ) in 7/31 (23%) cases of pediatric diffuse astrocytoma (WHO grades II-IV), consistent with subsequent findings from others, and is in contrast to adult GBMs, which infrequently show BRAF V600E mutation (12, 13) . In our series, BRAF T1799A occurred coincident with homozygous deletion of cyclin-dependent kinase inhibitor 2A (CDKN2A), encoding Ink4a-Arf in 5/7 cases (71%), suggesting the possibility of mechanistic cooperation between these two alterations in promoting glial tumor malignancy.
Here we investigated genetic requirements for generation of malignant astrocytomas in mice and used this information in preclinical testing. We show that expression of BRAF V600E mutation in combination with homozygous CDKN2A/Ink4a-Arf deletion is sufficient for formation of tumors with histology typical of malignant astrocytomas in humans. Further, we have used this mouse model, as well as human malignant astrocytoma xenografts with genetically faithful BRAF V600E and Ink4a-Arf mutations, to test a unique therapeutic strategy. We report that combination therapy with BRAF V600E and Cyclin-dependent kinase (CDK) 4/6 inhibitors has remarkable activity against intracranial tumors in vivo. Together our data suggest that it is possible to faithfully model the genetics of a subset of pediatric malignant astrocytomas in mice and to use combined murine and human tumor models as platforms for testing rational therapies.
Results

Strategy for Faithful Regulation of BRAF V600E Expression in Mouse
Neural Progenitor Cells to Model Pediatric Malignant Astrocytoma.
To precisely model activating mutations of BRAF found in pediatric astrocytomas, we used Braf CA mice carrying a genetically engineered knock-in allele of Braf (14) . The Braf CA allele expresses normal Braf in its nonrecombined configuration. However, upon exposure to bacteriophage P1 cre recombinase, the Braf CA allele is recombined to encode mutationally activated BRAF V600E at normal physiological levels of expression. By using the Braf CA allele in a heterozygous configuration, we precisely mimic the status of heterozygous BRAF mutations in human pediatric tumors (11) . We considered this strategy more accurate for investigating the expression of BRAF V600E than introduction by lentivirus, in which case the expression of a single splice variant of mutated BRAF would be driven by a strong viral promoter that is not subject to regulation by the factors involved in control of endogenous BRAF expression in normal or malignant cells. Indeed, the importance of faithful BRAF V600E regulation is indicated by other recent studies (14) (15) (16) (17) .
To assess whether BRAF activation alone is sufficient for tumor formation from neural progenitors (NPs), we crossed Braf CA/+ hemizygous mice to hGFAP-cre transgenic mice expressing cre under the control of the hGFAP promoter, which targets neural stem cells and astroglia in the developing brain (18) . The resulting hGFAP-cre; Braf CA compound heterozygous mice displayed an enlarged brain with expanded populations of type A neuroblasts in the subventricular zone, oligodendrocytes, and astroglia. Such animals survived until approximately 3 wk of age but did not demonstrate evidence of tumor development in the brain. Because of the lethality associated with BRAF V600E expression in these transgenic mice, we used an alternative system of orthotopic transplant of tumorigenic progenitor cells harvested from embryonic ventral telencephalon ( Fig. 1A) (19, 20) . hGFAP-cre; Braf CA/+ NPs were harvested and expanded for transplant into SCID mice by intracranial injection. In this experimental paradigm, mice undergo injection of 2 × 10 5 disassociated NP cells and are then monitored for symptoms indicative of tumor development. As shown in Table 1 , of five mice injected with cells expressing BRAF V600E alone, we observed no evidence of gross or microscopic tumor formation after 6 mo. We obtained similar results with NP cells derived from Olig2-cre; Braf CA/+ mice (n = 6, Table 1 ).
BRAF V600E Expression in Combination with Ink4a-Arf Loss of Function
Is Sufficient for Tumorigenesis. Braf CA/+ mice were then crossed with mice lacking Ink4a-Arf to test the influence of p16 Ink4a and p19 Arf tumor suppressor function. In contrast to the findings above, expression of BRAF V600E in Ink4a-Arf-deficient neurospheres (line 10740) was associated with tumor formation 3-4 mo after intracranial implantation (Table 1 and Fig. 1B ). We obtained comparable results in SCID mice injected with identical Braf CA/+ ; Ink4a-Arf −/− cells infected with an adenovirus encoding cre (Ad-cre; line 10776) ( Table 1 and Fig. 1B ). These findings indicate that expression of BRAF V600E cooperates with Ink4a-Arf deletion in tumor formation. Our results do not rule out the possibility of tumor formation at later time points, but nonetheless suggest that expression of BRAF V600E alone is insufficient to confer tumorigenicity to NPs.
Tumors exhibited restricted infiltration and tended to grow exophytically despite high mitotic index, nuclear pleomorphism, and expression of cellular markers typical of human pediatric astrocytoma, including Olig2, GFAP, and Nestin (21) (Fig. S1 ). Lines 10740 and 10776 were further manipulated by introduction of a luciferase reporter to allow noninvasive bioluminescence imaging (BLI). After passage in the murine brain, the tumors took on a highly infiltrative growth pattern characteristic of malignant astrocytoma with diffuse invasion throughout the cerebral hemisphere and extension along white matter tracts (see Fig. 4A ). Tumor cells exhibited marked pleomorphism, had a high mitotic index, and expressed phosphorylated ERK ( Fig. S2 ), which is an expected downstream consequence of BRAF activation. Because line 10776 demonstrated invasive histology and robustly expressed markers typical of pediatric astrocytoma including Olig2 (21) , it was prioritized for further study.
To further investigate cooperative interactions between BRAF V600E expression and Ink4a-Arf deletion, we injected Ad:cre into the subventricular zone of mice carrying Braf CA/+ alone or Braf CA/+ ; Ink4a-arf fl/fl (Fig. 1C ). No tumor formation was observed following injections of Braf CA/+ mice for up to 490 d postinjection ( Fig. 1D and Table 1 ). In contrast, intracranial tumor formation was observed in all Braf CA/+ Ink4a-arf fl/fl mice injected with Ad:cre (median survival, 70 d). These findings indicate that heterozygous BRAF V600E expression alone is insufficient to promote tumor development in vivo. In contrast, such BRAF V600E expression is transforming when combined with homozygous inactivation of Ink4a-Arf. Proliferation of Neural Progenitors. To further investigate the apparent cooperativity of BRAF V600E and Ink4a-Arf mutations, we cultured NPs that harbored these mutations. As shown in Fig. 2 , hGFAP-cre; Braf CA/+ ; Ink4a-Arf −/− cells have an increased proportion of bromodeoxyuridine (BrdU) positivity and a decreased apoptotic fraction compared with cells with intact p16 Ink4a . Moreover, Braf CA/+ cells lacking Ink4a-Arf have an impaired capacity to differentiate into neurons, oligodendrocytes, and astrocytes. Indeed, rather than differentiate, these cells proliferate even when subjected to differentiation culture conditions, as shown by their high Ki67-proliferative labeling indices ( Fig. 2 C and D).
CDK4/6 Activity Is Required for Cell Cycle Progression of BRAF V600E ;
Ink4a-Arf −/− Murine Astrocytoma Cells. p16 suppresses the activity of CDK4 and CDK6, which in turn antagonize retinoblastoma 1 (RB) activity to promote cell cycle progression. PD0332991 is an orally administered CDK4/6 inhibitor in clinical trials to assess efficacy against several types of cancer (22) . We decided to test whether elevated CDK4/6 activity is necessary to sustain cell cycle progression in BRAF V600E ; Ink4a-Arf −/− NP cells. PD0332991 treatment significantly reduced BrdU incorporation and increased the G1 phase fraction of BRAF V600E NP cells that were Ink4a-Arf − null, but not Ink4a-Arf intact ( Fig. 3 A and B) , suggesting that sustained CDK4/6 activity is necessary for cell cycle progression. Use of ImageJ to analyze and compare phosphorylated Rb (pRb) band intensity in treated vs. untreated cells, for replicate experiments and multiple Western blot analyses, consistently revealed 50-80% decrease in pRb for PD0332991-treated Ink4a-Arf −/− cells, relative to untreated Ink4a-Arf −/− cells, and following normalization of pRb signal against either corresponding total Rb or β-tubulin signal. Representative immunoblot results are shown in Fig. 3C .
Dual BRAF V600E and CDK4/6 Inhibition Shows Additive Effects Against
Murine 10776 Astrocytoma Progenitors in Vivo. PLX4720 is a tool compound of the PLX4032 inhibitor, which has yielded encouraging clinical results in patients with BRAF V600E metastatic melanoma (23) . We found significant therapeutic benefit of PLX4720 monotherapy against murine 10776 astrocytoma, as indicated by bioluminescence monitoring and survival of treated mice ( Fig. 4 B and C). Similarly, PD0332991 monotherapy provided a significant benefit ( Fig. 4 B and C). To determine possible additive antitumor activity, a treatment group was included to evaluate PLX4720 + PD0332991 combination therapy. Bioluminescence monitoring of this treatment group showed further reduction of intracranial tumor growth rate, relative to either monotherapy ( Fig. 4B ), as well as increased survival benefit ( Fig. 4C ). Analysis of intratumor Ki67 staining showed reduced proliferation in mono and dual PLX4720and PD0332991-treated samples compared with control tumors ( Fig. 4 D and E). There were significantly fewer Ki67 + cells in the samples treated with the combination therapy compared with either monotherapy.
Human GBM Cell Line with BRAF V600E Mutation and Deletion of CDKN2A Responds to Dual Inhibitor Therapy. We next extended results to a human malignant astrocytoma xenograft model, which used intracranial xenografts of the DBTRG05-MG astrocytoma cell line, previously determined as harboring BRAF V600E (24) , and for which we subsequently detected homozygous deletion of CDKN2A (25) . As with the 10776 cells, DBTRG05-MG cells were modified with luciferase to enable bioluminescence monitoring. DBTRG05-MG xenografts showed features of highgrade astrocytoma, such as invasion, anaplastic tumor cell morphology, Nestin expression, and high mitotic index ( Fig. 5A ). Consistent with results obtained with the murine allograft model, we found that treatment of DBTRG05-MG tumors with each monotherapy resulted in reduced tumor growth rate and conferred substantial survival benefit, and combination therapy significantly outperformed either monotherapy ( Fig. 5 B and C) . Results from the analysis of tumor Ki67 positivity also revealed consistency with those obtained with the murine model: all therapies significantly reduced malignant astrocytoma xenograft cell proliferation relative to the vehicle treatment group (Fig.  5D ). The treatment of a second human glioma line, AM-38, also showed combination therapy as being most effective at inhibiting tumor growth and extending animal survival ( Fig. S3 ).
To further address the importance of tumor cell BRAF V600E and CDKN2A-RB status as key determinants of tumor response to these small molecule inhibitors, we treated mice with intracranial GS2 malignant astrocytomas, that are wild type for BRAF, express p16 Ink4a , but lack RB protein ( Fig. S4) , with mono-and combination therapies as before with the other tumor models. GS2 tumors showed no response to either inhibitor ( Fig.  5 E and F) , demonstrating specificity of responses to PLX4720 and PD0332991, respectively.
To gain insight into the additional benefit of PLX4720 and PD0332991, we analyzed the signaling pathway responses to monotherapies and combination therapy ( Fig. S4 ). As expected, treatment of BRAF V600E CDKN2A −/− cells with the CDK4/6 inhibitor PD0332991 reduced RB phosphorylation, and treatment with the BRAF inhibitor PLX4720 suppressed phosphorylation of extracellular signal-regulated kinase (ERK) and MAPK/ERK kinase (MEK). Surprisingly, however, treatment of BRAF V600E CDKN2A −/− cell lines with PLX4720 alone resulted in elevated phosphorylation of the serine-threonine protein kinase AKT, which returned to basal level phosphorylation when cells were cotreated recipient animals, it is possible that higher BRAF V600E expression levels might pass a tumorigenesis threshold. Indeed, overexpression of BRAF V600E using retrovirus, which might drive higher levels of BRAF activity or target higher numbers of suitable progenitors, is sufficient to produce pilocytic astrocytomas in mice (31) .
In contrast, we found that heterozygous BRAF V600E expression combined with Ink4-Arf deficiency abrogated NP cell cycle arrest and conferred tumorgenicity to BRAF V600E -expressing NPs when transplanted orthotopically into SCID mice or when activated in subventricular zone NP in situ. These results are consistent with observations reported in a recent study where BRAF V600E was overexpressed in Ink4a-Arf −/− neonatal brain using a retroviral vector (32) and indicate that the coincidence of BRAF-activating mutation and deletion of CDKN2A may represent obligatory steps during initiation and/or malignant progression of a subset of pediatric astrocytomas. One possibility is that BRAF V600E induces p16 expression, promoting cell cycle arrest, as has been reported in human neural stem cells and v-raf-1 murine leukemia viral oncogene homolog 1 (RAF)expressing human fibroblasts (33) (34) (35) . From these data we conclude that expression of BRAF V600E triggers an oncogene-induced senescence-like (OIS) response, which is mediated by elevated p16 expression ( Fig. S5 ). If so, when BRAF V600E expression is triggered in Ink4a-Arf deficient cells there is no OIS and tumor progression is permitted.
Our previously published survey of gene alterations in diffuse pediatric astrocytomas, which included analysis of tumor copy number variation as well as investigation of selected cancer-associated genes, such as BRAF and P53, revealed no other gene alteration with BRAF T1799A other than homozygous CDKN2A deletions (11) . In addition, the DBTRG05-MG and AM-38 astrocytoma lines that we used here do not carry additional alterations other than PTEN inactivation in DBTRG05-MG (25) . These results do not exclude the possibility of other gene alterations acting in combination with BRAF V600E to promote tumorigenesis, such as the missense mutation of histone H3.3 encoding H3F3A, which has been reported in a significant proportion of pediatric GBMs (6, 7) , but the results do support CDKN2A inactivation as being especially effective in cooperating with BRAF V600E for promoting tumor development.
We noted that hGFAP-cre; BRAF V600E ; Ink4a-Arf −/− mousederived astrocytomas initially showed a propensity for exophytic growth. Interestingly, in a recent study (13) , BRAF V600E mutations have been associated with pleomorphic xanthoastrocytoma (PXA), a superficial human astrocytic tumor that can grow exophytically. Although this study did not address CDKN2A status, deletion of CDKN2A has independently been identified in pediatric pleomorphic xanthoastrocytomas (36) (37) (38) . Future work is needed to determine whether the BRAF V600E , p16-deficient astrocytomas we describe may initially be tropic for superficial growth.
Combinatorial Therapy May Be Efficacious for a Genetic Subset of Pediatric Astrocytomas. The finding of cooperativity between BRAF V600E activation and Ink4a-Arf deficiency in murine and human cells has therapeutic implications; namely, that combined inhibition of CDK4/6 and BRAF V600E could prove efficacious in treating malignant astrocytomas with these gene alterations. In the present study, we found that both murine and human BRAF V600E mutant, Ink4a-Arf-deficient astrocytomas respond to the BRAF V600E inhibitor PLX4720, as indicated by a reduced rate of intracranial tumor growth and extended survival. These results are consistent with our previous report using PLX4720 to inhibit RAF activity in nonpediatric astrocytoma models (39) and suggest that PLX4720 has a favorable biodistribution for use in treating BRAF V600E -driven brain cancers. Importantly, when we combined PLX4720 with the CDK4/6 inhibitor PD0332991, we observed additive antitumor effects. Our report uniquely indicates that the two inhibitors can be used in combination for increasing antitumor effect, due to therapeutic targeting of distinct enzymatic activities. Interestingly, the paradoxical increase in AKT phosphorylation following PLX4720 treatment can be reversed by cotreatment with PD0332991. This result lends further support to the use of combination therapy for treating BRAF V600E and CDKN2A-deficient tumors. Taken together, our data support the importance of tumor genotype for predicting response to each therapy, used singularly or in combination. We note that no animal subjects with intracranial BRAF V600E -p16 null tumors, from any of the three in vivo efficacy experiments (Figs. 4 and 5 and Fig. S3 ), died while receiving combination therapy. This observation raises the question of how long survival can be extended by continuous combination therapy, and related studies are underway to address this question.
Appropriate genetic diagnostic tests are available for identifying tumors with BRAF mutation and also lacking CDKN2A, and their routine application to pediatric and adult malignant astrocytomas would reliably identify patients who might benefit from this combination therapy. The frequency of BRAF V600E mutations in pediatric glioblastomas is estimated between 6 and 18% (11, 13) , whereas the frequency in adult glioblastomas is estimated to be 1-3% (13, 40) . In pediatric anaplastic astrocytomas (WHO grade III), we found BRAF V600E in 3 of 23 cases (13%, ref. 39 ). The frequency of BRAF V600E in pediatric grade III astrocytomas has not been published by others. For adult anaplastic astrocytomas, no instances of V600E were determined among 51 cases. In total, these results suggest that BRAF V600E occurs at a significant frequency among WHO grade III and grade IV pediatric astrocytomas, but is rare among corresponding adult tumors.
Our data, although suggestive, need to be further examined in a preclinical setting to address length of benefit from this therapy, as well as possible tumor adaptation to therapy. Nonetheless, our preliminary results are promising for this approach providing effective treatment for appropriately diagnosed CNS cancer patients.
Materials and Methods
Neural Progenitor and Glioblastoma Cultures. Mouse neurosphere cultures were established from E14.5 basal progenitors, as previously described (20) , with the modification that cells were grown in the presence of EGF and basic FGF (20 ng/mL each). AM-38 human glioblastoma cells were obtained from the Japan Health Sciences Foundation Health Science Research Resources Bank; DBTRG05-MG human glioblastoma cells were obtained from the American Type Culture Collection. Cells were propagated in Eagle's MEM supplemented with 10% FBS and nonessential amino acids. GS2 cells were obtained from Manfred Westphal, University Hospital Eppendorf, Hamburg, Germany, and maintained as neurosphere cultures, as previously described (41) .
Intracranial Injections of Tumor Cells and Cre-Expressing Adenovirus. Tumor cells were transplanted into the brains of SCID mice (ICRSC-M; Taconic) as previously described (20), at the following coordinates, according to Bregma: 1.0 mm (anterior), 2.0 mm (lateral), and 3.0 mm (deep). Alternatively, cells were transplanted into athymic mice (5-wk-old female, nu/nu genotype, BALB/c background; Simonsen Laboratories) as previously described (42) . Braf CA/+ and Braf CA/+ Ink4a-arf fl/fl 60-d-old mice were injected with 2 μL of adenovirus (10 9 multiplicity of infection, MOI) in which cre recombinase expression is regulated by a ubiquitous promoter (Vector Biolabs). The following coordinates, according to Bregma, were used: 1.0 mm (anterior), 1.0 mm (lateral), and 1.8 mm (deep).
Treatment of Tumor-Bearing Athymic Mice with BRAF V600E and CDK4/6 Inhibitors. Athymic mice transplanted with luciferase-modified 10776, DBTRG05-MG, or AM-38 cell lines were randomly assigned to vehicle control (DMSO or 50 mM sodium lactate, pH 4, for PLX or PD0332991, respectively), PLX treatment (PLX4720; Plexxikon), PD treatment (PD0332991, Pfizer), or a combination of PLX and PD treatments. The treatment group received a daily dose of 10 mg/kg of PLX by i.p. injection and/or oral administration of 150 mg/kgof PD for 14 consecutive days. All mice were monitored every day for the development of symptoms related to tumor growth and twice weekly by BLI. Mice were killed when they exhibited symptoms indicative of significant impairment to neurological function.
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Huillard et al. 10 For proliferation and apoptosis assays, neurosphere cultures were dissociated and plated at a density of 10 4 cells per well onto eightwell polylysine/laminin-coated slides (BD). Cells were allowed to adhere for 24 h and fixed with 4% (wt/vol) paraformaldehyde (PFA). Bromodeoxyduridine (BrdU, 10 μM) was added 30 min before fixation. For differentiation assays, cells on coated slides were switched to growth factor-free medium 24 h after plating. Cultures were maintained for 7 d and fixed in 4% PFA. Cells were immunostained using standard protocols with anti-BrdU (1/100; BD Pharmingen), anticleaved caspase 3 (1/500; Cell Signaling), anti-GFAP (1/2,000; Sigma), anti-βIII-tubulin (TuJ1, 1/1,000; Covance), anti-O4 (1/100; Chemicon), and anti-Ki67 (1/500; BD Pharmingen).
Modification of Tumor Cells with Firefly Luciferase-Expressing
Reporter. DBTRG05-MG, 10776, and AM-38 cells were transduced with a lentivirus encoding the firefly luciferase (Fluc) under the control of the spleen focus forming virus (SFFV) promoter, as previously described (3). Cells were screened for transfection efficiency by treatment with luciferin (D-luciferin potassium salt, 150 mg/kg; Gold Biotechnology) in vitro and examination by a IVIS Lumina system (Xenogen). More than 80% of cells were transfected.
Flow Cytometry. To examine G1 cell cycle arrest induction by PD0332991, 1.0 × 10 6 cells were plated into 6-cm dishes and allowed to adhere overnight. Cells were treated with PD0332991 (1 μM in 50 mM sodium lactate, pH 4) for 18 h. Equal volumes of sodium lactate were used as treatment controls. Cells were pulsed with 10 μmol/L bromodeoxyuridine (BrdU) for 1 h, trypsinized, and centrifuged. Cells were fixed and stained using the FITC BrdU Flow kit (Pharmingen), counterstained with 7amino-actinomycin D (7-AAD), and analyzed by flow cytometry in a BD FACSCalibur instrument using FlowJo 8.8 software. . Therapeutic response of orthotopic AM-38 human astrocytoma xenografts to BRAF and CDK4/6 inhibitors. Intracranial tumors generated from the AM-38 astrocytoma line were treated with PD0332991, PLX4720, or PLX4720 + PD0332991 therapies for 14 consecutive days (pink area). (A) Bioluminescence imaging (BLI). P values for differences between growth curves on day 21 were calculated. P = 0.0121 for control vs. PLX + PD combination therapy. There are no statistically significant differences in tumor growth rate between control vs. PLX (P = 0.5027) or PD (P = 0.1746). Although there is a trend for the combination being superior, there are no significant differences in tumor growth rate between PD or PLX vs. PD/PLX treatment groups: P = 0.0506 for combination vs. PLX, and P = 0.1820 for combination vs. PD. (B) Kaplan-Meier survival curves; P = 0.0028 for control vs. PLX, P = 0.0005 for control vs. PD0332991; P < 0.001 for PLX or PD vs. PLX4720 + PD0332991 combination therapy. . Characterization of the activated signaling pathways following BRAF V600E and CDK4/6 inhibition in AM-38, DBTRG05-MG, U87, and GS2 cell lines. Cells were serum starved for 16 h and treated for 1 h with either EGF (25 ng/mL), EGF (25 ng/mL) + PLX4720 (10 mM), EGF (25 ng/mL) + PD0332991 (10 mM), or EGF + PLX4720 (10 mM) + PD0332991 (10 mM). Solid black rectangles indicate the expected pMAPK and pERK suppressive effects following BRAF inhibition with PLX4720. Note that pMEK and pERK are unexpectedly induced by PLX4720 in U87 and GS2 lines (solid gray rectangles). Dotted black rectangles indicate the expected pRB suppressive effect of PD0332991 in the p16-deficient AM-38, DBTRG05-MG, and U87 cells. We noted an unexpected induction of pAKT following PLX4720 treatment on BRAF V600E AM-38 and DBTRG05-MG cells (dashed black rectangles), and this induction was suppressed by cotreatment with PD0332991 (dashed gray rectangles).
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CDKN2A p16 Ink4a PLX4720 PD0332991 Cell Cycle Progression MEK ERK1/2 CDK4/6 RB1 Fig. S5 . BRAF V600E and p16 pathway interactions and therapeutic implications. Diagram depicts relevant mutations in a subset of pediatric astrocytoma (blue ovals). Present findings suggest that in neural progenitors, heterozygous BRAF V600E mutation alone leads to induction of p16 expression (dashed arrow), which in turn results in enhanced RB1 activity and inhibition of cell cycle progression. We speculate this provides selective pressure for biallelic inactivation of CDKN2A in human astrocytomas. Inhibitors PLX4720 and PD0332991 show individual and additive therapeutic effects in genetically faithful preclinical models.
